仲西 昌太郎 (ナカニシ ショウタロウ)

Nakanishi Shotaro

写真a

職名

助教

科研費研究者番号

40725321

現在の所属組織 【 表示 / 非表示

  • 専任   琉球大学   医学部   附属病院   助教  

取得学位 【 表示 / 非表示

  • 琉球大学 -  学士  その他 / その他

職歴 【 表示 / 非表示

  • 2013年04月
    -
    継続中

      琉球大学 医学部附属病院 泌尿器科 助教  

論文 【 表示 / 非表示

  • Coexisting congenital mid-ureteral stricture and megaureter due to ureterovesical junction obstruction: A case report.

    Nakanishi S, Miyazato M, Tanaka K, Uema N, Saito S

    Urology case reports ( Urology Case Reports )  40   101877   2022年01月 [ 査読有り ]

    掲載種別: 研究論文(学術雑誌)

  • Hypophysitis induced by ipilimumab and nivolumab combination therapy for advanced renal cell carcinoma: A case report.

    Motonaga A, Nakanishi S, Tanaka K, Nishida S, Izumi K, Saito S

    Urology case reports ( Urology Case Reports )  38   101661 - 101661   2021年09月 [ 査読有り ]

    掲載種別: 研究論文(学術雑誌)

     概要を見る

    Ipilimumab and nivolumab combination therapy is effective against unresectable or metastatic renal cell carcinoma. However, it is associated with many immune-related adverse events, including hypophysitis that is difficult to diagnose early because of non-specific initial symptoms. Herein, we report the case of a 54-year-old man with metastatic renal cell carcinoma who developed hypophysitis after receiving ipilimumab and nivolumab combination therapy. The initial symptom was headache. However, endocrine tests showed decreased levels of cortisol, free thyroxine and thyroid-stimulating hormone. Moreover, magnetic resonance imaging revealed pituitary enlargement. Accordingly, we diagnosed hypophysitis and immediately started hydrocortisone replacement therapy, which improved the symptoms.

  • Impact of prior intravesical bacillus Calmette-Guerin therapy on the effectiveness of pembrolizumab for patients with metastatic urothelial carcinoma.

    Taoka R, Kobayashi T, Hidaka Y, Abe H, Ito K, Kojima T, Kato M, Kanda S, Hatakeyama S, Matsui Y, Matsushita Y, Naito S, Shiga M, Miyake M, Muro Y, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Kamiyama M, Morita S, Ogawa O, Nishiyama H, Kitamura H, Sugimoto M, Japan Urological Oncology Group.

    Urologic oncology ( Urologic Oncology: Seminars and Original Investigations )    2021年08月 [ 査読有り ]

    掲載種別: 研究論文(学術雑誌)

  • Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis.

    Kobayashi M, Narita S, Matsui Y, Kanda S, Hidaka Y, Abe H, Tsuzuki T, Ito K, Kojima T, Kato M, Hatakeyama S, Matsushita Y, Naito S, Shiga M, Miyake M, Muro Y, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Taoka R, Kamiyama M, Morita S, Habuchi T, Ogawa O, Nishiyama H, Kitamura H, Kobayashi T, Japan Urological Oncology Group.

    BJU international ( BJU International )    2021年06月 [ 査読有り ]

    掲載種別: 研究論文(学術雑誌)

     概要を見る

    OBJECTIVES: To assess the impact of histological variants on survival and response to treatment with pembrolizumab in patients with chemo-resistant urothelial carcinoma (UC). PATIENTS AND METHODS: The medical records of 755 patients with advanced UC who received pembrolizumab were reviewed retrospectively. Patients were classified into pure UC (PUC) and each variant. Best overall response (BOR) and overall survival (OS) were compared between the groups using a propensity score matching (PSM). RESULTS: Overall, 147 (19.5%) patients harboured any histological variant UC (VUC). After PSM, there were no significant differences in the objective response rate (ORR, 24.5% vs 17.3%, P = 0.098) or disease control rate (DCR, 36.7% vs 30.2%, P = 0.195) when comparing patients with any VUC and PUC. Furthermore, any VUC, as compared with PUC, was associated with a similar risk of death (hazard ratio [HR] 0.90, 95% confidence interval [CI] 0.68-1.20; P = 0.482). Squamous VUC, which was the most frequent variant in the cohort, had a comparable ORR, DCR and OS as compared with PUC or non-squamous VUC. The patients with sarcomatoid VUC (n = 19) had significantly better ORR (36.8%, P = 0.031), DCR (52.6%, P = 0.032), and OS (HR 0.37, 95% CI 0.15-0.90; P = 0.023) compared to patients with PUC. CONCLUSIONS: The presence of variant histology did not seem to affect BOR or OS after pembrolizumab administration in patients with chemo-resistant UC. The patients with sarcomatoid VUC achieved favourable responses and survival rates compared to PUC.

  • Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer.

    Nakanishi S, Goya M, Tamaki M, Oshiro T, Saito S

    BMC research notes ( BMC Research Notes )  14 ( 1 ) 227 - 227   2021年06月 [ 査読有り ]

    掲載種別: 研究論文(学術雑誌)

     概要を見る

    OBJECTIVE: To date, there are no useful markers for predicting the prognosis of metastatic hormone-sensitive prostate cancer (mHSPC). We evaluated the effect of early changes in prostate-specific antigen (PSA) levels after androgen deprivation therapy (ADT) on castration-resistant prostate cancer (CRPC) progression and overall survival (OS) in mHSPC patients. RESULTS: In 71 primary mHSPC patients treated with ADT, the median times to CRPC and OS were 15 months and 92 months, respectively. In multivariate analysis, a Gleason score of ≥ 8 (p = 0.004), an extent of disease value (EOD) of ≥ 2 (p = 0.004), and a 3-month PSA level > 1% of the pretreatment level (p = 0.017) were independent predictors of shorter time to CRPC. The area under the receiver operating characteristic curve was feasible at 0.822. A 3-month PSA level > 1% of the pretreatment level was an independent predictor of OS (p = 0.004). Three factors were independent predictors of shorter time to CRPC. A 3-month PSA level > 1% of the pretreatment level correlated with a poor prognosis.

全件表示 >>

科研費獲得情報 【 表示 / 非表示